{"Title":"Homology Medicines","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"67","Founded":"","Address":"","Phone":"(781) 301-7277","Web_address":"http://www.homologymedicines.com","Market_cup":"$541.2mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-29.99 mil (last 12 months)","Symbol":"FIXX","Exchange":"NASDAQ","Shares":"9.0","Price_range":"$16.00 - $16.00","Est_volume":"$144.0 mil","Manager":"BofA Merrill Lynch/ Cowen/ Evercore ISI","CO_managers":"BTIG","Exp_to_trade":"3/28/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Our proprietary platform is designed to utilize our human hematopoietic stem cell derived adeno-associated virus vectors, or AAVHSCs, to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders."}